NGBiLab S3.E16: Cerebro Therapeutics
Impossible d'ajouter des articles
Échec de l’élimination de la liste d'envies.
Impossible de suivre le podcast
Impossible de ne plus suivre le podcast
NGBiLab S3.E16: Cerebro Therapeutics
-
Lu par :
-
De :
Cerebro Therapeutics is a biotech company based in Quebec City developing disease-modifying treatments for neurodegenerative disorders, with a primary focus on Parkinson's.
Unlike current therapies that only manage symptoms, Cerebro is working to stop the disease from progressing altogether.
In this episode, Jim Wilson speaks with president and co-founder Martin Levesque about a company that spun directly out of his research lab at Laval University.
Martin explains the science behind their approach, which combines immunotherapy and gene therapy to deliver protective antibodies across the blood-brain barrier in a single injection, and how a striking result in a mouse model convinced him the work needed to reach patients.
Martin also reflects on the leap from academic researcher to startup founder, the support of the Michael J. Fox Foundation, and why he believes the first treatment to halt Parkinson's could be made in Canada.
